Navigation Links
Cell-permeable peptide shows promise for controlling cardiovascular disease
Date:4/17/2013

Philadelphia, PA, April 16, 2013 Atherosclerosis sometimes called "hardening of the arteries" is a leading cause of death and morbidity in Western countries. A cell-permeable peptide containing the NF-ĸB nuclear localization sequence (NLS) shows promise as a potential agent in controlling the development of atherosclerotic disease. This study is published in the May 2013 issue of The American Journal of Pathology.

Atherosclerosis is a chronic inflammatory disease of the arterial and vascular wall. The objective of many therapeutic compounds is to modulate atherogenesis the process that leads to the formation of fatty tissue-containing plaques that stick to the cell wall. Numerous cellular and molecular inflammatory components are involved in the disease process, and uncontrolled activation of pro-inflammatory transcription factors, such as nuclear factor-B (NF-ĸB), plays a significant role. Several NF-ĸB inhibitors are in phase II-III clinical trials against various inflammatory diseases, but most cardiovascular research is still in the preliminary laboratory experimental phase.

Investigators in Spain, the United States, the United Kingdom, and Germany studied the anti-inflammatory and atheroprotective effects of a cell-permeable peptide containing the NF-ĸB NLS. In vitro tests clearly established that NLS peptide blocks the nuclear import of activated NF-ĸB and inhibits NF-ĸB activation in vascular cells. These findings were corroborated in vivo in ApoE knockout mice, an experimental model relevant to human atherosclerosis. In these experiments, the mice were fed a high-fat diet and treated with either NLS peptide or vehicle (control group).

The results showed that systemic administration of NLS peptide reduced the nuclear NF-ĸB activity in vascular smooth muscle cells (VSMCs) and macrophages of aortic plaques of mice. More importantly, NLS peptide inhibited lesion development in mice either at the onset of atherosclerosis (early treatment) or after the development of advanced plaques (delayed treatment), without affecting serum cholesterol levels. The results also demonstrated that NLS peptide alters plaque composition and inflammation in atherosclerotic lesions.

"The NF-ĸB system is a crucial factor regulating the expression of genes in different steps of the atherosclerotic process, from early phases characterized by lipid modification, chemotaxis, adhesion of leukocytes, monocyte differentiation, foam cell formation, and inflammatory cytokine expression to more advanced lesions involving cell death, migration and proliferation of VSMCs, and fibrous cap formation," explained lead investigator Carmen Gomez-Guerrero, PhD, of the Renal and Vascular Inflammation Laboratory, IIS-Fundacin Jimnez Daz, Autonoma University, Madrid, Spain.

"Our study demonstrates that targeting NF-ĸB nuclear translocation hampers inflammation and atherosclerosis development and identifies cell-permeable NLS peptide as a potential anti-atherosclerotic agent," she said. "These properties make cell-permeable NLS peptide a promising prevention/intervention strategy to inhibit inflammation in cardiovascular diseases."


'/>"/>

Contact: David Sampson
ajpmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. A new avenue to better medicines: Metal-peptide complexes
2. Under the right conditions, peptide blocks HIV infection at multiple points along the way
3. Unique peptide could treat cancers, neurological disorders, and infectious diseases
4. Genetic survey of endangered Antarctic blue whales shows surprising diversity
5. University of Houston study shows BP oil spill hurt marshes, but recovery possible
6. Weakness can be an advantage in surviving deadly parasites, a new study shows
7. Study shows unified process of evolution in bacteria and sexual eukaryotes
8. Sexual reproduction brings long-term benefits, study shows
9. UCSB study shows forest insects and diseases arrive in US via imported plants
10. Study shows botanical formula fights prostate cancer
11. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/20/2016)... 2016 A market that just keeps on ... the explosion in genomics knowledge. Learn all about it ... range of dynamic trends are pushing market growth and ... - pharmacogenomics - pathogen evolution - next generation sequencing ... greater understanding of the role of genetic material in ...
(Date:1/20/2016)... 2016  Synaptics Incorporated (NASDAQ: SYNA ), ... announced sampling of S1423, its newest ClearPad ® ... screen applications including smartwatches, fitness trackers, and touch ... rectangular shapes, as well as thick and curved ... on screen, while wearing gloves, and supports swipes ...
Breaking Biology News(10 mins):
(Date:2/12/2016)... ... ... Global Stem Cells Group has announced an inaugural conference and stem cell ... 24-March 6, 2016. The new facility will provide advanced protocols and state-of-the-art techniques in ... CEO Benito Novas will host the event, which will begin with a stem cell ...
(Date:2/12/2016)... FRANCISCO , February 12, 2016 ... Medicine Efforts by Enabling Scientific Understanding of Complex ... and Rare Diseases --> ... genomic diagnostics in South Asia and a leading provider ... would contribute $10 million to the GenomeAsia 100K ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016  Bioethics International, ... how medicines are researched, developed, marketed and made accessible to ... BMJ Open had named the publication of the ... for 2015. The publication is also featured as one of ... published in the last year that are most frequently read. ...
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
Breaking Biology Technology: